Efficacy and safety of trilaciclib to prevent chemotherapy-induced myelosuppression in advanced solid tumors: a systematic review and meta-analysis

Key Points

• Trilaciclib significantly reduces chemotherapy-induced myelosuppression in patients with advanced solid tumors.
• Analysis revealed a 30% reduction in incidence rates of severe myelosuppression when using trilaciclib.
• Systematic review and meta-analysis across multiple studies support the efficacy of trilaciclib as a prophylactic intervention.
• Using trilaciclib in chemotherapy enhances treatment tolerability, highlighting its potential clinical importance.